Hypertension Drugs Market Size was valued at USD 439.67 Billion in 2023. The Global Hypertension Drugs industry is projected to grow from USD 472.58 Billion in 2024 to USD 780.96 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.74% during the forecast period (2024 - 2032).
Study objectives of Middle-East and Africa Hypertension Drugs Market:
Middle-East and Africa Hypertension Drugs Market by TypeÂ
Intended Audience
Market Synopsis of Middle-East and Africa Hypertension Drugs Market:
Market Scenario:
The Middle-East and Africa Hypertension Drugs Market is projected to reach USD 6,985.6 Million by 2030 at 6.1% CAGR during the forecast period 2022-2030. Hypertension or high blood pressure is the condition when blood pressure increases to the unhealthy level. Hypertension is very harmful and it can lead to stroke, heart failure, heart attack and kidney diseases. The main purpose of anti-hypertension drug is to lower and control high blood pressure to protect organs like brain, heart, kidneys. Hypertension affects four out of ten adults in Middle East and Africa region. Over 1.5 million deaths occurs due to hypertension in Middle East and Africa. Countries in Middle East and Africa bear a heavy burden from hypertension diagnosis and treatment. Huge funding in R&D and various initiatives by government are driving the growth for Hypertension Drugs Market in Middle East and Africa.
Middle-East and Africa Hypertension Drugs Market has been segmented on the basis of type which comprise Thiazide diuretics, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, Calcium channel blockers, Renin inhibitors, Alpha blockers, Alpha-beta blockers, Central-acting agents, Vasodilators, Aldosterone antagonists, and others.
Considering the Middle-East and Africa Hypertension Drugs Market scenario, UAE region is believed to be the largest market for Middle-East and Africa Hypertension Drugs. Moreover Saudi Arabia market is also growing and second largest market for Hypertension Drugs. On the other hand, Egypt market is expected to grow at the steady pace in the Middle-East and Africa Hypertension Drugs during the forecasted period. Rest of the Middle East and Africa region is likely to have a limited but steady growth in the market.
Key Players for Middle-East and Africa Hypertension Drugs Market: Â Â
The report for Middle-East and Africa Hypertension Drugs Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
| Report Attribute/Metric | Details |
| Market Size 2023 | 439.67 (USD Billion) |
| Market Size 2024 | 472.58 (USD Billion) |
| Market Size 2032 | 780.96 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 5.74 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Â Â Geographies Covered | Â Â UAE, Saudi Arabia, Egypt |
| Â Â Key Vendors | Â Â Abbott (US), Johnson & Johnson Services, Inc. (US), Novartis (Switzerland), GlaxoSmithKline plc.(UK), AstraZeneca (UK), Bayer AG (Germany), Pfizer Inc.(US), Merck & Co., Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Gilead (US) |
| Â Â Key Market Opportunities | Â Â Joint ventures, strategic alliances, mergers and acquisitions, new product developments |
| Â Â Key Market Drivers | Â Â technological advancement, macro economical and governing factors |
Hypertension Drugs Market Highlights:
Frequently Asked Questions (FAQ) :
Global Middle East and Africa Hypertension Drugs Market is projected to grow at a 5.74% CAGR between 2024-2032
Global Middle East and Africa Hypertension Drugs Market is predicted to touch USD 780.96 Million by 2032.
The UAE is predicted to dominate the Middle East and Africa Hypertension Drugs Market.
Various government initiatives and huge funding in research and development are boosting market growth.
Key competitors in the Middle East and Africa Hypertension Drugs Market include Gilead (US), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Merck & Co., Inc. (US), Pfizer Inc. (US), Bayer AG (Germany), GlaxoSmithKline plc. (UK), AstraZeneca (UK), Novartis (Switzerland), Johnson & Johnson Services, Inc. (US), and Abbott (US).
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
